Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks

ACTTION will sponsor the Second International Conference on Accelerating the Development of Enhanced Pain Treatments (ADEPT-II) on June 15-17, 2016 in Washington DC. This meeting will be devoted to the design, execution, analysis, and interpretation of clinical trials of pain treatments and will focus on important advances that have occurred since the successful ADEPT-I meeting held in Bermuda in March 2011. The intended audience is investigators in academia, industry, and government who are involved with any of these aspects of clinical trials of pain treatments. The impetus for the meeting is the lag in the development of analgesic treatments with improved efficacy and safety, coupled with the shortage of junior investigators with knowledge of the issues involved in the successful design and conduct of analgesic trials. The meeting will begin with a half-day session on preclinical and translational pain research, which will be followed by 2 full days on the design, execution, analysis, and interpretation of analgesic trials. Because a range of experience among the participants is expected, morning plenary sessions will be followed by parallel afternoon introductory and advanced tracks. ACTTION will offer 10 fellowships for junior investigators to attend the meeting that will cover all of their travel and registration expenses. The members of the ADEPT-II Steering Committee are Ralf Baron, MD, PhD; Allan Basbaum, PhD; Robert Dworkin, PhD; Sharon Hertz, MD; Troels Jensen, MD, PhD; Nathaniel Katz, MD; Allison Lin, PharmD, PhD; Srinivasa Raja, MD; Michael Rowbotham, MD; and Dennis Turk, PhD.